The Global Migraine Therapeutics Market to grow at a CAGR of 5.38% during the period 2018-2022.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The growth in the number of migraine treatment awareness programs will be a key trend driving the market growth. The extensively prevalent and disabling nature of this neurological disorder is providing traction to awareness programs. Several organizations are conducting such programs for educating and helping the patients suffering from migraine.
According to the report, the increasing number of patients suffering from migraine will drive the market growth. Migraine is a extensively prevalent neurological disease globally, and impacts the population during puberty and young adulthood. It is more prevalent in women due to the rapid fluctuations in female reproductive hormones, estrogen levels that affect the cells in the brain.
Further, the report states that the side effects of migraine drugs will impact the market growth. Several migraine therapeutics have numerous side effects such as drowsiness, weight gain, insomnia, muscle weakness, chest pressure, warm sensations, and agitation. The beta-blockers migraine therapeutics have side effects such as depression, fatigue, nausea, insomnia, and lowered blood pressure.
- Alder BioPharmaceuticals
- Eli Lilly and Company
- Teva Pharmaceutical Industries
Key Topics Covered
1. Executive Summary
2. Scope of the Report
3. Research Methodology
4. Market Landscape
5. Market Sizing
6. Five Forces Analysis
7. Market Segmentation by Product
8. Market Segmentation by Treatment
9. Customer Landscape
10. Regional Landscape
11. Decision Framework
12. Drivers and Challenges
13. Market Trends
14. Vendor Landscape
15. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/vsn6x6/global_migraine?w=4